H.C. Wainwright has reiterated its $300 price target for Centrus Energy (NYSE: LEU), the US-based nuclear fuel supplier, as the firm continues to benefit from rising demand for advanced nuclear fuel. The brokerage's stance reflects confidence in Centrus's role in supplying high-assay low-enriched uranium (HALEU), a critical component for next-generation reactors.
Centrus Energy has been a focal point for investors tracking the nuclear renaissance, particularly in the United States where government support for HALEU production has strengthened. The company is one of the few Western suppliers capable of producing the fuel, which is needed for small modular reactors (SMRs) and other advanced designs. H.C. Wainwright's maintained target suggests analysts see sustained upside, though the stock remains subject to regulatory and geopolitical risks.
For UK investors, the news arrives against a backdrop of renewed interest in nuclear energy domestically. The UK government has committed to expanding nuclear capacity as part of its net-zero strategy, with SMRs expected to play a role. While Centrus is not directly listed in London, exposure to the nuclear theme is available through ETFs and investment trusts focused on clean energy or infrastructure. Pension funds with diversified global equity allocations may also hold indirect stakes.
The broader market context is noteworthy: the FTSE 100 was trading around 8,250 on Monday, down 0.3% amid cautious sentiment ahead of central bank decisions. Energy stocks were mixed, with BP and Shell edging lower as oil prices slipped. The nuclear sector, however, has been a relative outperformer year-to-date, driven by policy tailwinds and rising electricity demand from data centres and AI.
Analysts at H.C. Wainwright did not provide additional commentary beyond the price target reiteration. However, the move underscores the view that Centrus is well-positioned to capitalise on long-term uranium demand, even as short-term volatility persists. For UK readers with exposure to global energy equities, the nuclear theme remains one to watch, particularly as the UK pushes ahead with its own SMR programme.